Examples of 'tocilizumab' in a sentence
Meaning of "tocilizumab"
tocilizumab (noun) - a medication used to treat various inflammatory conditions, such as rheumatoid arthritis. It is often prescribed by healthcare professionals
Show more definitions
- A human monoclonal antibody against the interleukin-6 receptor. Used to attenuate counterproductive immune responses in certain diseases (autoimmune or infectious).
How to use "tocilizumab" in a sentence
Basic
Advanced
tocilizumab
Tocilizumab has been found to be effective in a number of patients.
Pharmacokinetic parameters of tocilizumab did not change with time.
But tocilizumab treatment eliminated this effect.
It contains the active substance tocilizumab.
Tocilizumab must be available in case of cytokine release syndrome.
It is unknown whether tocilizumab is excreted in human breast milk.
Tocilizumab normalises expression of these enzymes.
Availability of tocilizumab and site qualification.
Tocilizumab is a drug that suppresses the immune system.
Promising results are achieved with mycophenolate and tocilizumab.
Tocilizumab for thyroid eye disease.
The medicines tested were tocilizumab and sarilumab.
Tocilizumab is most commonly used to treat rheumatoid arthritis.
The active substance is tocilizumab.
Tocilizumab versus adalimumab in monotherapy.
See also
Some people have serious infections while taking tocilizumab.
The excretion of tocilizumab in milk has not been studied in animals.
There are no adequate data from the use of tocilizumab in pregnant women.
Tocilizumab was well tolerated.
The available evidence for tocilizumab does not allow for it to be recommended.
Tocilizumab is an immunosuppressive drug.
Treatment for latent infection should be initiated prior to tocilizumab use.
How tocilizumab work.
Tisagenlecleucel continues to expand and persist following administration of tocilizumab and corticosteroids.
Anakinra and tocilizumab are medications that block the action of certain interleukins.
These results are consistent with those observed in patients treated with intravenous tocilizumab.
Reduction of tocilizumab dose due to laboratory abnormalities has not been studied in pJIA patients.
The difference between survival rates between tocilizumab and infliximab was statistically significant p.
Reduction of tocilizumab dose due to laboratory abnormalities has not been studied in sJIA patients.
The overall clinical adverse event profile was similar between tocilizumab and adalimumab.
Mean predicted tocilizumab exposure parameters were similar between the two body weight groups.
The change now saves two steps before reimbursement for tocilizumab is considered.
Tocilizumab treatment was associated with significant increase in cholesterol levels and in total adverse events.
No clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation were reported.
The retention rates significantly differed among patients on use of infliximab when compared to tocilizumab p.
Tocilizumab and emergency equipment should be available prior to infusion and during the monitoring period.
This data does not suggest a relevant risk for cancer initiation and progression under tocilizumab treatment.
Tocilizumab now listed on Quebec drug formulary.
Treatment with the drug tocilizumab can reduce CRS symptoms.
Tocilizumab is being studied for pulmonary arterial hypertension PAH.
YESCARTA continues to expand and persist following administration of tocilizumab and corticosteroids.
MTX to tocilizumab monotherapy resulted in increased frequency of these elevations.
RoActemra contains the active substance tocilizumab.
Tocilizumab is beneficial in decreasing RA disease activity and improving function.
Good luck with Tocilizumab.
The approval of tocilizumab is based on a phase III study called CHERISH.
Limit to a maximum total of 4 tocilizumab doses.
Tocilizumab is the first medication approved by Health Canada that specifically treats systemic JIA.
Has the patient tried tocilizumab for their disease?
Repeat tocilizumab as needed at a minimum interval of 8 hours if there is no clinical improvement.
